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ABSTRACT 
Background: 
Although there are sex differences in management and outcome of acute coronary syndromes 
(ACS), sex is not a component of Global Registry of Acute Coronary Events (GRACE) risk score (RS) 
for in-hospital mortality prediction. We sought to determine the prognostic utility of GRACE RS in 
men and women, and whether its predictive accuracy would be augmented through sex-based 
modification of its components.  
Methods: 
Canadian men and women enrolled in GRACE and Canadian Registry of Acute Coronary Events 
were stratified as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment 
elevation ACS (NSTE-ACS). GRACE RS was calculated as per original model. Discrimination and 
calibration were evaluated using the c-statistic and Hosmer-Lemeshow goodness-of-fit test, 
respectively. Multivariable logistic regression was undertaken to assess potential interactions of 
sex with GRACE RS components.   
Results: 
For the overall cohort (n=14422), unadjusted in-hospital mortality rate was higher in women than 
men (4.5% vs. 3.0%, p<0.001). Overall, GRACE RS c-statistic and goodness-of-fit test p-value were 
0.85 (95%CI 0.83-0.87) and 0.11, respectively. While the RS had excellent discrimination for all 
subgroups (c-statistics >0.80), discrimination was lower for women compared to men with STEMI 
[0.80 (0.75-0.84) vs. 0.86 (0.82-0.89), respectively, p<0.05]. The goodness-of-fit test showed good 
calibration for women (p=0.86), but suboptimal for men (p=0.031). No significant interaction was 
evident between sex and RS components (all p>0.25).  
Conclusions: 
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The GRACE RS is a valid predictor of in-hospital mortality for both men and women with ACS. The 
lack of interaction between sex and RS components suggests that sex-based modification is not 
required. 
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Introduction 
Women with acute coronary syndrome (ACS) tend to present with more atypical 
symptoms, which pose diagnostic challenges and often lead to delays to the correct diagnosis.[1, 
2] More importantly, women have higher risk profiles at presentation and higher mortality rates 
compared to their male counterparts.[3, 4] It has been postulated that the worse outcomes in 
women may be partly due to their older age at presentation (generally 10 years older), and as 
such, women may have more comorbidities, carry a higher burden of coronary artery disease, and 
a greater propensity for decompensation at presentation.[1, 2] However, a sub-population of 
younger women presenting with ACS has also been shown to have worse prognosis than men.[5] 
Thus, it is also plausible that there are sex-related pathophysiology differences that impact ACS 
disease progression and outcomes.[6] The Global Registry of Acute Coronary Events (GRACE) was a 
large, prospective, international registry that led to the creation of a simple eight variable risk 
score (RS) to predict in-hospital mortality in ACS patients.[7, 8] Although the GRACE RS was 
developed over a decade ago, the most recent guidelines by international societies continue to 
recommend its use,[9, 10] suggesting that GRACE remains a relevant risk stratification tool. 
Despite the well-recognized sex-related disparities in the management and outcome of 
ACS, sex is not a component of the GRACE RS. Further, there is a lack of data as to whether the 
predictive accuracy of the RS varies based on sex, highlighting the need for sex-specific validation 
of GRACE. Hence, we sought to determine whether the GRACE RS predicts in-hospital mortality 
equally well in men and women, and ascertain whether its predictive accuracy can be augmented 
through sex-based modification of its components.  
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Methods 
Study population 
The full details for the design of GRACE, expanded GRACE (GRACE
2
), and Canadian Registry 
of Acute Coronary Events (CANRACE) have been published elsewhere.[8] Briefly, patients included 
in this study were those who participated in prospective, multicenter observational registries, and 
admitted with presumed ACS in 53 hospitals across Canada from June 1999 to December 2008.[7] 
GRACE started in 1999 and expanded to involve more hospitals in 2003 for GRACE
2
. After 
completion of GRACE
2
, Canadian hospitals continued recruitment of participants in CANRACE until 
2008. Participants were eligible if they met the following inclusion criteria: ш ? ?ǇĞĂƌƐof age; 
presumed diagnosis of ACS secondary to cardiac ischemia defined as at least one of the following 
features: abnormal serum biomarkers of myocardial necrosis, electrocardiographic changes 
consistent with ACS, or documented evidence of coronary artery disease (CAD). Participants were 
excluded if the ACS might have been precipitated by non-cardiovascular comorbidity, such as 
trauma. Research ethics approval was obtained from respective hospital ethics or institutional 
review boards. All study participants provided informed consent where required.  
Study design 
We stratified the patients with respect to sex and ACS subtype [ST-segment elevation 
myocardial infarction (STEMI), or non-ST-segment elevation ACS (NSTE-ACS) including non-STEMI 
(NSTEMI) and unstable angina (UA)]. The GRACE RS was calculated for all patients according to the 
original model to predict in-hospital mortality, which comprised age, heart rate, systolic blood 
pressure, Killip class, cardiac arrest, creatinine, ST-deviation and elevated cardiac biomarkers.[8] 
Of note, in the original derivation of the GRACE risk model, sex was a significant predictor of in-
hospital mortality in univariate analysis but not in multivariable analysis.[8]   
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The primary outcome was all-cause mortality during index hospitalization, which was 
identical to that of the original GRACE RS. We also examined in-hospital rates of myocardial 
(re)infarction (re-MI), heart failure, and cardiogenic shock.  
Statistical analysis 
We compared baseline characteristics between the patient groups using Mann-Whitney U 
ĂŶĚWĞĂƌƐŽŶʖ ?ƚĞƐƚfor continuous and categorical data, respectively. The GRACE model 
performance for in-hospital mortality risk prediction in men and women was assessed based on 
discrimination and calibration.[11] ŝƐĐƌŝŵŝŶĂƚŝŽŶƌĞƉƌĞƐĞŶƚƐƚŚĞŵŽĚĞů ?ƐĂďŝůŝƚǇƚŽcorrectly 
classify patients into high versus low risk for developing the event of interest(i.e., in-hospital 
mortality for GRACE RS). To compare discrimination in men and women, the c-statistic was 
computed from the area under the receiver operator characteristic (ROC) curve. A model with a c-
statistic of ш0.75 is considered to have acceptable discriminatory ability.[11] The calibration of a 
model compares the agreement between the predicted and observed event rates. The Hosmer-
Lemeshow goodness-of-fit test was employed to evaluate calibration. This test divides patients 
into deciles according to their RS and compares the predicted versus the observed rates of the 
outcome. A significant p-value indicates a lack-of-fit and suboptimal calibration. 
In the original GRACE RS, sex was not included as a component. We performed individual 
multivariable logistic regressions to assess for potential interactions of sex with each of the GRACE 
RS predictor variables. A significant interaction between sex and a GRACE RS component would 
suggest that the prognostic significance of the component of interest is different between men 
and women. All statistical analyses were performed using SPSS version 22 (IBM). A 2-sided p<0.05 
was considered statistically significant for all analyses.  
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GRACE and CANRACE were sponsored by an unrestricted grant from Sanofi-Aventis and 
Bristol-Myers Squibb. The industrial sponsors had no involvement in the current study conception 
or design; collection, analysis, and interpretation of data; writing, review, or approval of the 
manuscript; and the decision to submit the manuscript for publication.  
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Results 
Table 1 provides a summary of baseline patient characteristics. In total, 14,422 Canadian 
patients with ACS were included in this study [9,603 (67.6%) men; 4,819 (33.4%) women]; 4,043 
had STEMI and 10,379 had NSTE-ACS. Overall, women were older than men (median 73 versus 64 
years), more likely to have diabetes, hypertension, heart failure, angina, peripheral vascular 
disease, and stroke. Women were less likely to have had prior cardiovascular interventions 
including percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery, 
and tended to have higher Killip class on initial presentation. The median GRACE RS was 
significantly higher in women than men.  
For inpatient management of ACS, women less frequently received an antiplatelet (aspirin 
or clopidogrel), a GP IIb/IIIa inhibitor, and heparin compared with men (Supplementary Table S1). 
Women with STEMI also received less fibrinolysis. Moreover, women were less likely to undergo 
coronary angiography, PCI, or CABG.  
Figure 1 summarizes the in-hospital outcomes stratified by sex and ACS classification. In the 
overall cohort, the unadjusted in-hospital mortality rate was significantly higher in women than 
men (4.5% versus 3.0%, p<0.001). Women had significantly higher unadjusted rates of re-MI (5.0% 
versus. 3.8%, p<0.001), the composite endpoint of re-MI and mortality (9.0% versus 6.4%, 
p<0.001), heart failure (11.8% versus 9.2%, p<0.001), and major bleeding  (2.5% versus 1.8%, 
p<0.005). These sex differences in unadjusted rates of in-hospital events were observed 
irrespective of ACS subgroup. 
Although women had higher unadjusted in-hospital mortality rate than men, addition of 
sex to the original GRACE RS components in multivariable logistic regression failed to demonstrate 
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female sex as an independent predictor of in-hospital mortality [adjusted odds ratio 1.20, 95% 
confidence interval (CI) 0.97-1.49, p=0.09]. 
The GRACE RS showed good discrimination for the overall cohort, with c-statistic of 0.85 
(95% CI 0.83-0.87) (Table 2). The GRACE RS also showed excellent discrimination for all subgroups, 
whereby all c-statistic >0.80 (Table 2). For the overall cohort, discrimination for women was 
significantly lower compared with men. When considering ACS subtype, the lower GRACE RS 
discrimination in women was observed for STEMI and not NSTE-ACS.  
The GRACE RS showed adequate calibration in the overall cohort (Hosmer-Lemeshow 
goodness-of-fit p-value 0.11; Figure 2A). While the goodness-of-fit test showed good calibration 
for women (Hosmer-Lemeshow p-value=0.86, Figure 2B), calibration was suboptimal for men 
(Hosmer-Lemeshow p-value=0.031, Figure 2C). Comparison of predicted versus observed in-
hospital mortality risk demonstrates that GRACE RS tended to overestimate the risk for men, while 
it predicted in-hospital mortality risk in women more accurately.    
There was no significant interaction between sex and the GRACE RS components (all p-
values ш0.25, Supplementary Table S2), suggesting that the prognostic significance of each 
predictor variable was similar for men and women.  
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Discussion 
We validated the original GRACE model for the risk stratification of both Canadian men and 
women presenting with ACS. The GRACE RS showed excellent model discrimination for in-hospital 
mortality, irrespective of sex or ACS subtype. Although discrimination was slightly better in men, 
the lack of interaction between sex and GRACE RS components suggests that the prognostic 
significance of each GRACE RS component was similar among men and women.  
We found that women had significantly worse outcomes compared with men. The 
unadjusted relative in-hospital mortality risk was 50% greater in women compared to men, with 
the highest mortality rate in women with STEMI. The reasons for worse outcomes in women are 
likely multifactorial, owing to sex-differences in baseline characteristics and presenting clinical 
features known to modulate prognosis, as well as treatment gaps. As compared to men, our 
population of women was older, harbored more cardiovascular risk factors and comorbidities. 
Similarly, fewer women underwent coronary angiography, PCI, or CABG during index 
hospitalization. Taken together, our results corroborate with previous findings that high-risk 
women (harboring higher GRACE RS) likely received suboptimal treatment, which might have 
contributed to poorer outcomes.[5, 12-14] 
Model indices are essential in the evaluation of risk stratification model performance. The 
c-statistics for men and women with STEMI or NSTE-ACS were all above 0.75,[11] a threshold 
generally considered to reflect good risk stratification. This suggests that GRACE RS is a useful tool 
to identify high-risk patients who may benefit from early aggressive management. However, our 
study did demonstrate that GRACE RS discrimination was slightly lower for women compared to 
men, particularly for STEMI.  
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The precise reason for the poorer discrimination in women with STEMI is difficult to 
discern. A previous study has confirmed the utility of GRACE RS in both STEMI and NSTE-ACS.[15] 
However, it was unclear whether components of the GRACE RS should be assigned sex-specific 
weights in the model to improve prediction of outcomes. Here, we showed that sex-specific 
interaction terms with RS components did not improve GRACE risk prediction, suggesting that sex-
based modification of GRACE predictor variables would likely not increase accuracy of risk 
stratification. In keeping with this, women had significantly higher GRACE RS compared with men, 
indicating that the model appropriately accounted for the greater mortality risk at presentation. 
Moreover, given that treatment is not a component of GRACE RS, it is plausible that differential 
treatment may result in disparities in accuracy of in-hospital mortality prediction (particularly for 
STEMI patients), even for patients with similar GRACE RS.  
In contrast to discriminatory power, the GRACE model calibration was adequate for 
women, but suboptimal for men. Thus, caution is required when interpreting the predicted 
probability of in-hospital mortality in men by GRACE RS. Several reasons may contribute to this 
finding. As aforementioned, this study and previous observational studies have concordantly 
demonstrated that both medical and interventional strategies are underutilized in women 
compared to men. Women with NSTE-ACS tend to be managed conservatively without undergoing 
invasive coronary angiography.[16-18] Similarly, not only do women present later during 
STEMI,[19] they are less frequently referred for coronary angiography.[20] Although overall ACS 
mortality rates have decreased in recent years, it is plausible that these dissimilarities led to a 
disproportionate smaller decline in mortality of women compared to men.[21, 22] In addition, the 
original GRACE RS was developed in a multi-national cohort with diverse geographic variations in 
risk factors, treatment patterns, and outcomes.[23] Previous studies have demonstrated 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
13 
 
considerable geographic variation in ACS outcomes.[24, 25] As such, an overestimation of the 
mortality risk for Canadian men by GRACE might be partly attributed to better outcomes in 
Canadian men compared to men of other geographical regions. Furthermore, the Hosmer-
Lemeshow goodness-of-fit test p-value is dependent on sample size, with tendency towards 
significance for larger sample sizes. In this cohort, the sample size of men was close to double that 
of women, resulting in greater power to detect minor differences in predicted versus observed 
event rates among men. Finally, the incidence of in-hospital mortality was generally low and thus, 
a statistical difference between predicted and actual mortality rates may be less clinically relevant. 
Indeed, the absolute difference of predicted versus observed mortality rate in men was 
predominantly small in the range of 0.14-0.40% for deciles 1-9. An exception to this is the small 
number of patients in decile 10, whereby the absolute difference was 2.53%. Overall, we postulate 
that the imprecision in predicted mortality rates may be clinically inconsequential for the majority 
of men with ACS.   
Amongst the ACS risk stratification tools, the GRACE, TIMI, and PURSUIT models are the 
most widely validated and adopted in clinical practice. Of these, PURSUIT is the only one that 
incorporated sex as a predictor variable of mortality; however, its use is limited to NSTE-ACS 
patients.[26] Similar to GRACE, the TIMI RS for STEMI found sex as a significant predictor of 30-day 
mortality, but was not incorporated in the final model.[27] Subsequent studies also found that 
TIMI RS was appropriate for predicting risk irrespective of sex.[28, 29] Comparing the GRACE RS 
calibration to that of other risk models is complicated by the fact that most validation studies only 
used discrimination in evaluating the predictive accuracy.[30] An earlier study validating the in-
hospital GRACE RS in Canadian ACS patients enrolled between late 1990s to early 2000s, showed 
both good calibration and discrimination.[31] Conversely, a subsequent study also indicated 
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suboptimal calibration but good discrimination in the overall cohort of Canadian patients.[32] 
Taken together, the slight imprecise prediction of in-hospital mortality probability in men may 
warrant future recalibration in face of evolving improvements in treatments and patient 
outcomes. 
Study strengths and limitations 
Our study is not without limitations. Although the study design aimed to enroll an unbiased 
patient population, selection bias might have remained. While consecutive enrolment of eligible 
patients was encouraged, this could not be verified across centers. Patients with very early death 
and complications from ACS might be underrepresented in the registry, creating a survivorship 
bias. The rate of revascularization interventions may not reflect current practice, as it has likely 
increased since completion of the registry. Although we have proposed several potential 
explanations for the inadequate calibration in men, the precise reason could not be identified. 
Similarly, the reason for the slightly better discrimination of GRACE RS in men compared with 
women also requires further investigation. Our study might not be adequately powered to test for 
interactions. While we evaluated sex-based predictive accuracy of in-hospital mortality, potential 
sex-differences in the accuracy of GRACE 6-month mortality model for long-term outcomes may 
exist. Of note, our primary objective was not to derive a new risk model for men and women, but 
to assess the validity of GRACE RS use in a sex-independent manner. Finally, future studies are 
required to confirm our findings in other patient populations.  
Despite the limitations, our study has several strengths. This is the first study, to our knowledge, to 
systematically conduct a sex-based validation of the GRACE RS in predicting in-hospital mortality 
for the broad spectrum of ACS patients. Validation of the original GRACE model supports the 
continued relevance of the original predictor variables, despite evolution in diagnosis and 
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treatment patterns. The study population herein had broad inclusion and few exclusion selection 
criteria. Hence, the population likely closely reflects the diverse array of ACS encountered in 
everyday  “ƌĞĂůǁŽƌůĚ ?clinical practice. Taken together, our data support the routine use of GRACE 
RS in contemporary clinical practice to risk stratify ACS patients, irrespective of sex.  
Conclusions 
The GRACE RS remains an accurate and robust risk stratification tool for both men and 
women presenting with ACS, serving as a useful guidance for treatment decisions. Although 
presenting features are different between men and women, the prognostic significance of GRACE 
RS components did not differ according to sex in predicting in-hospital mortality. These findings 
suggest that sex-based modification of GRACE RS is likely not required.  
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Table 1 Baseline characteristics of NSTE-ACS and STEMI patients stratified by sex. 
 
  All patients 
(n=14422) 
STEMI (n=4043) NSTE-ACS (n=10379) 
   Male 
(n=2831) 
Female 
(n=1212) 
P value Male 
(n=6772) 
Female 
(n=3607) 
P value 
        
Age, years
 a
 67 (57-77) 61 (53-
72) 
73 (60-
81) 
<0.001 65 (56-
75) 
72 (61-
80) 
<0.001 
Cardiovascular 
risk factors, % 
       
 Diabetes  27.4  20.9 25.5 0.0010 28.2 31.6 <0.001 
 Hypertension 60.1  45.5 61.7 <0.001 59.8 71.6 <0.001 
 Smoking 26.8 36.3 29.7 <0.001 26.3 19.1 <0.001 
 Dyslipidemia 53.4 45.2 42.3 0.086 58.5 54.1 <0.001 
Prior 
cardiovascular 
comorbidities, % 
       
 MI 32.7 25.0 22.2 0.056 36.8 34.7 0.033 
 Angina 43.6 26.5 27.5 0.43 49.2 52.0 0.008 
 HF 10.8 7.6 12.4 <0.001 9.8 14.4 <0.001 
 Stroke/TIA 9.2 6.1 9.1 0.0010 8.5 12.8 <0.001 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
 PVD 8.8 7.0 7.7 0.42 9.8 8.7 0.065 
Prior 
cardiovascular 
interventions, % 
       
 PCI 17.4 11.1 8.9 0.030 21.3 18.1 <0.001 
 CABG  12.3  7.7 4.4 <0.001 16.9 10.1 <0.001 
Clinical features 
at presentation 
       
 Cardiac arrest, 
% 
1.5 3.5 2.4 0.055 0.9 0.7 0.45 
 Systolic BP, 
mmHg
 a
 
143 (125-
162) 
140 
(122-
159) 
140 
(120-
161) 
0.41 144 
(126-
161) 
146 
(127-
166) 
<0.001 
 Diastolic BP, 
mmHg
 a
 
80 (69-91) 83 (71-
95) 
78 (66-
90) 
<0.001 80 (70-
92) 
77 (66-
88) 
<0.001 
 Heart rate, 
BPM
 a
 
78 (66-93) 77 (64-
92) 
80 (67-
98) 
<0.001 77 (65-
92) 
80 (68-
95) 
<0.001 
 Killip class, %        
  I 83.6 84.4 75.6 <0.001 85.7 81.6 <0.001 
  II 10.7 9.9 13.7  9.8 12.1  
  III/IV 5.7 5.7 10.7  4.5 6.3  
 ST deviation, % 46.2 84.5 80.0 0.001 31.0 33.4 0.014 
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 Abnormal 
cardiac 
biomarker at 
presentation, % 
47.9 57.6 62.3 0.005 44.3 42.1 0.036 
 Creatinine, 
ʅmol/L a 
93 (78-
113) 
96 (84-
115) 
86 (71-
108) 
<0.001 96 (83-
116) 
83 (70-
106) 
<0.001 
GRACE risk score
 a
 127 (103-
157) 
133 
(114-
160) 
153 
(128-
180) 
<0.001 118 (95-
147) 
128 
(104-
158) 
<0.001 
a
 Median (25
th
 and 75
th
 percentiles). 
Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass graft surgery; HF, 
heart failure; MI, myocardial infarction; NSTE-ACS, non ST elevation acute coronary syndrome; 
PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST elevation 
myocardial infarction; TIA, transient ischemic attack. 
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Table 2 Comparison of GRACE risk score c-statistic and Hosmer-Lemeshow goodness-of-fit P value 
for ACS patients stratified by sex. 
  Male (n=9603) Female (n=4819) P value 
All patients (n=14422)    
 c-statistic (95% CI) 0.86 (0.84-0.88) 0.82 (0.79-0.85) 0.034 
 Hosmer-Lemeshow 
goodness-of-fit P value 
0.031 0.86  
STEMI (n=4043)    
 c-statistic (95% CI) 0.86 (0.82-0.89) 0.80 (0.75-0.84) 0.042 
NSTE-ACS (n=10379)    
 c-statistic (95% CI) 0.85 (0.82-0.89) 0.82 (0.79-0.86) 0.20 
Abbreviations: ACS, acute coronary syndrome; CI, confidence interval; NSTE-ACS, non-ST-elevation 
ACS; STEMI, ST-elevation myocardial infarction. 
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Figure 1 Unadjusted rates of in-hospital mortality and complications. Patients are stratified by sex 
and type of ACS, either ST-elevation myocardial infarction, or non-ST elevation ACS.  
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Figure 2 GRACE risk score calibration plot comparing between observed and predicted in-hospital 
mortality rates (%). Patients are divided into 10 deciles, with each point representing one decile. 
The x-axis shows the observed unadjusted in-hospital mortality rate. The y-axis shows the 
predicted in-hospital mortality rate by GRACE risk score. The dashed line shows absolute 
agreement between observed and predicted rates. (A) All ACS patients. (B) Women with ACS. (C) 
Men with ACS. 
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